HTBX Heat Biologics Inc.

0.45
-0.00  -1%
Previous Close 0.45
Open 0.46
Price To book 2.05
Market Cap 16122905
Shares 35,788,912
Volume 109,563
Short Ratio 2.88
Av. Daily Volume 548,457

SEC filingsSee all SEC filings

  1. 8-K - Current report 171210973
  2. 424B2 - Prospectus [Rule 424(b)(2)] 171210938
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171209635
  4. EFFECT - Notice of Effectiveness 171198108
  5. 8-K - Current report 171193044

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing data released March 21, 2017. Noted September 12, 2017 that a Type C meeting with FDA has been scheduled.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)

Latest News

  1. Here’s What’s Behind Heat Biologics Inc (HTBX) Drop Today
  2. Heat Biologics Prices 5,813,950 Shares for Common Stock Offering
  3. Heat Biologics Announces Proposed Public Offering of Common Stock
  4. Is It Time To Buy Heat Biologics Inc (HTBX)?
  5. Heat Biologics Reports Third-quarter 2017 Results and Corporate Update
  6. Heat Biologics Presents Follow-up Data on its ComPACT(TM) T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
  7. Heat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
  8. Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives Second Tranche of its $15.2 Million CPRIT Grant Award
  9. Heat Biologics Rights Offering Materials Available for Shareholders of Record
  10. Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards
  11. Heat Biologics Announces Pricing for Rights Offering to Stockholders and Participating Warrant Holders
  12. UPDATE: Heat Biologics to Present at the Upcoming BIO Investor Forum in San Francisco
  13. Before You Buy Heat Biologics Inc’s (HTBX), You Should Consider This
  14. Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
  15. Heat Biologics Announces Expected Calendar for Rights Offering
  16. Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma to Advance Cancer-targeting Immunotherapies
  17. Heat Biologics Announces Common Stock Rights Offering in Form S-1 Filing
  18. Heat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance with Listing Requirements
  19. Today's Research Reports on Stocks to Watch: Advaxis and Heat Biologics
  20. Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer

SEC Filings

  1. 8-K - Current report 171210973
  2. 424B2 - Prospectus [Rule 424(b)(2)] 171210938
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171209635
  4. EFFECT - Notice of Effectiveness 171198108
  5. 8-K - Current report 171193044
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171193008
  7. 8-K - Current report 171188308
  8. 8-K - Current report 171181062
  9. 8-K - Current report 171178281
  10. S-3 - Registration statement under Securities Act of 1933 171160975